Mitochondrial dysfunction in Parkinson's disease
Parkinson's disease (PD) is the second most common neurodegenerative disease. About
2% of the population above the age of 60 is affected by the disease. The pathological …
2% of the population above the age of 60 is affected by the disease. The pathological …
[HTML][HTML] New insights into the complex role of mitochondria in Parkinson's disease
New discoveries providing insights into mitochondrial bioenergetics, their dynamic
interactions as well as their role in cellular homeostasis have dramatically advanced our …
interactions as well as their role in cellular homeostasis have dramatically advanced our …
Cell biology and pathophysiology of α-synuclein
α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve
terminals. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) …
terminals. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) …
[HTML][HTML] Parkinson's disease: animal models and dopaminergic cell vulnerability
J Blesa, S Przedborski - Frontiers in neuroanatomy, 2014 - frontiersin.org
Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the
global population over 65 years of age. A hallmark feature of PD is the degeneration of the …
global population over 65 years of age. A hallmark feature of PD is the degeneration of the …
α-Synuclein in Parkinson's disease
L Stefanis - Cold Spring Harbor perspectives in …, 2012 - perspectivesinmedicine.cshlp.org
α-Synuclein is a presynaptic neuronal protein that is linked genetically and
neuropathologically to Parkinson's disease (PD). α-Synuclein may contribute to PD …
neuropathologically to Parkinson's disease (PD). α-Synuclein may contribute to PD …
[HTML][HTML] Parkinson's disease: mechanisms and models
W Dauer, S Przedborski - Neuron, 2003 - cell.com
Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the
substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic …
substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic …
Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis
The protein α-synuclein accumulates in the brain of patients with sporadic Parkinson's
disease (PD), and increased gene dosage causes a severe, dominantly inherited form of …
disease (PD), and increased gene dosage causes a severe, dominantly inherited form of …
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation
Two subjects with Parkinson's disease who had long-term survival of transplanted fetal
mesencephalic dopaminergic neurons (11–16 years) developed α-synuclein–positive Lewy …
mesencephalic dopaminergic neurons (11–16 years) developed α-synuclein–positive Lewy …
Neurotoxin-based models of Parkinson's disease
J Bové, C Perier - Neuroscience, 2012 - Elsevier
Animal experimentation in the Parkinson's disease (PD) field is a classic example of how the
use of animal models to study diseases can have a significant impact on human health …
use of animal models to study diseases can have a significant impact on human health …
A guide to neurotoxic animal models of Parkinson's disease
K Tieu - Cold Spring Harbor perspectives in …, 2011 - perspectivesinmedicine.cshlp.org
Parkinson's disease (PD) is a neurological movement disorder primarily resulting from
damage to the nigrostriatal dopaminergic pathway. To elucidate the pathogenesis …
damage to the nigrostriatal dopaminergic pathway. To elucidate the pathogenesis …